Crescent Biopharma, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation oncology therapeutics for patients with solid tumors. The company's pipeline is built around precision-engineered biologics, leveraging multiple modalities and established targets to create potentially transformative single-agent and combination therapies. Its lead clinical program, CR-001, is a proprietary tetravalent anti-PD-1/anti-VEGF bispecific antibody designed to deliver improved clinical efficacy and safety compared to existing standard-of-care treatments. In addition to its bispecific antibody programs, Crescent is advancing a portfolio of novel antibody-drug conjugates (ADCs), including CR-002, a topoisomerase inhibitor ADC targeting PD-L1.
Crescent Biopharma became a publicly traded entity in June 2025 through a reverse merger with GlycoMimetics, Inc., following which the combined company redomesticated to the Cayman Islands while maintaining its operational headquarters in Waltham, Massachusetts. As a pre-commercial, clinical-stage company, Crescent does not currently generate product revenue and relies on capital raises and strategic partnerships to fund its research and development activities. Notably, the company has established a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical to expand its pipeline and accelerate combination strategies for its therapeutic candidates.
